Hansoh Pharmaceutical Group Company Limited announced that "HS-20106 Injections" (the "Product"), a Category 1 therapeutic biological product has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China. The specific indication will be determined after the completion of clinical research.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.26 HKD | -2.17% | -5.47% | +3.17% |
Apr. 30 | Hansoh Pharmaceutical’s 2023 Profit Up 27% | MT |
Apr. 29 | Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.17% | 12.6B | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.26% | 238B | |
+7.12% | 204B | |
-5.73% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- 3692 Stock
- News Hansoh Pharmaceutical Group Company Limited
- Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections